Axsome Therapeutics (NASDAQ: AXSM)
Axsome Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Axsome Therapeutics Company Info
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
News & Analysis
Axsome Delivers Strong Q3 Revenue Beat
Axsome Therapeutics surpassed revenue expectations in Q3, driven by strong sales from its key products.
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Yes, bargains can still be found in the stock market.
1 Under-the-Radar Biotech Stock to Buy and Hold
It could be an industry giant in the making.
Why Axsome Therapeutics Stock Is Sinking Today
Investors were unhappy with Axsome's worse-than-expected Q2 loss.
Axsome: Revenue Surges, Net Loss Widens
Axsome Therapeutics posted strong revenue growth, but faced significant operational losses and rising costs.
Should You Buy This Sinking Stock on the Dip?
The biotech isn't having the best year.
Why Axsome Therapeutics Stock Is Sinking Today
A short-seller report is causing a sell-off of the biotech stock.
Prediction: These 2 Growth Stocks Could Triple By 2030
These companies have a habit of silencing the bears.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.